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Abstract
Background: Patients are becoming increasingly involved in research which can promote innovation through
novel ideas, support patient-centred actions, and facilitate drug development. For rare diseases, registries that
collect data from patients can increase knowledge of the disease’s natural history, evaluate clinical therapies,
monitor drug safety, and measure quality of care. The active participation of patients is expected to optimise
rare-disease management and improve patient outcomes. However, few reports address the type and
frequency of interactions involving patients, and what research input patient groups have. Here, we describe
a collaboration between an international group of patient organisations advocating for patients with atypical
haemolytic uraemic syndrome (aHUS), the aHUS Alliance, and an international aHUS patient registry
(ClinicalTrials.gov NCT01522183).
Results: The aHUS Registry Scientific Advisory Board (SAB) invited the aHUS Alliance to submit research ideas
important to patients with aHUS. This resulted in 24 research suggestions from patients and patient
organisations being presented to the SAB. The proposals were classified under seven categories, the most
popular of which were understanding factors that cause disease manifestations and learning more about the
clinical and psychological/social impact of living with the disease. Subsequently, aHUS Alliance members
voted for up to five research priorities. The top priority was: “What are the outcomes of a transplant without
eculizumab and what non-kidney damage is likely in patients with aHUS?”. This led directly to the initiation of
an ongoing analysis of the data collected in the Registry on patients with kidney transplants.
Conclusion: This collaboration resulted in several topics proposed by the aHUS Alliance being selected as
priority activities for the aHUS Registry, with one new analysis already underway. A clear pathway was
established for engagement between a patient advocacy group and an international research network. This
should ensure the development of a long-term partnership which clearly benefits both groups.
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Background
In recent years, patients have become increasingly active
in managing their own healthcare, in terms of both
treatment decision-making processes and research par-
ticipation. Thus, many patient organisations are actively
engaging with clinical investigators and pharmaceutical
companies. This new model has been shown to promote
innovation, support patient-centred actions, and facili-
tate the development of new treatments [1]. While many
patient advocacy groups may work closely with scientists
and clinicians, there are few publications available describ-
ing the type of interactions that occur, how regularly they
occur and what input to the research programme the
groups have [2, 3].
The problems of rare disease research
In the case of rare diseases, the development of effective
treatment strategies can be hampered by a lack of know-
ledge of the condition. Issues include a lack of basic re-
search on the natural history of the disease and difficulty
in recruiting sufficient patients for effective clinical tri-
als. Furthermore, the research that is performed may not
answer the questions considered most important by pa-
tients [4]. Patient registries have been identified as tools
to increase knowledge of the natural history of rare dis-
eases, as well as providing a real-world setting in which
clinical therapies, drug safety, and quality of care can be
monitored [5]. Registries also provide a cohort of pa-
tients who may be suitable for enrolment into subse-
quent therapeutic trials. A global registry may also be
the only way to collect sufficient data for robust statis-
tical analyses. The active participation of patients will
therefore lead to improved management of rare-diseases
and patient outcomes [6].
Patient engagement in research can be interpreted in
several ways, such as information sharing amongst rare
disease groups and the use of patient-driven registries to
facilitate data collection. However, such activities do not
give patients input to the research process; for a success-
ful registry, providing a voice for patients to help recruit-
ment, encourage active participation and influence the
research agenda is key. Although there may occasionally
be reluctance on the part of patients and academics to
engage in partnerships with industry, the significant
effort and costs of a patient registry are best met
through public/private partnership [7, 8]. Therefore en-
hancing communication and understanding between
these groups is imperative.
Atypical haemolytic uraemic syndrome
Atypical haemolytic uraemic syndrome (aHUS) is a rare
genetic, life-threatening, chronic disease of children and
adults caused by unregulated activation of the alternative
complement pathway leading to systemic thrombotic
microangiopathy (TMA) [9, 10]. A complement abnor-
mality is described in 50–60% of patients but identifica-
tion is not required for diagnosis [9, 11, 12].
Presentation can initially be mild, with patients reporting
fatigue and influenza-like symptoms, or sudden and se-
vere. aHUS often manifests as nonimmune microangio-
pathic haemolytic anaemia, thrombocytopenia, and
acute organ failure. Historically, patients with aHUS had
a poor prognosis with high morbidity due to chronic
kidney disease, frequent graft failure after renal trans-
plantation and high mortality rates [11, 12]. Differential
diagnosis is based on exclusion of TMA caused by Shiga
toxin-producing Escherichia coli-induced HUS and
thrombotic thrombocytopenic purpura [9]. Other causes
of TMA including (but not limited to) disorders of me-
tabolism, drug toxicity and malignant hypertension
should also be excluded [13]. Eculizumab, an anti-
human C5 monoclonal antibody, is nowadays recom-
mended for the treatment of aHUS following successful
clinical trials in paediatric and adult patients with aHUS
[14–16].
The Global aHUS Registry
The Global aHUS Registry (US National Institutes of
Health www.ClinicalTrials.gov Identifier NCT01522183)
is an observational, non-interventional, multicentre
registry of patients with aHUS, and is a product of a
partnership between worldwide academia, patients with
aHUS and Alexion Pharmaceuticals, Inc. The aims of
the Registry are to assess the long-term patient out-
comes, and collect and evaluate safety and effectiveness
data specific to the use of eculizumab, fulfilling post-
marketing regulatory requirements. The Global Registry
is open to patients of all ages with a clinical diagnosis of
aHUS; an identified complement gene mutation or fac-
tor H autoantibody is not required. Patients with sec-
ondary aHUS are eligible and physicians can record the
potential precipitating cause. Patient data are collected
following a research protocol and in accordance with
International Conference on Harmonisation Good Clin-
ical Practice Guidelines and the Declaration of Helsinki.
Clinical and patient reported data (e.g. a fatigue score
completed by the patient) are collected at study enrol-
ment and every 6 months thereafter. The methodology
of the aHUS Registry and characteristics of the first 516
patients enrolled (from 16 countries) have recently been
published [17]. Amongst this patient cohort, 60% had
received plasma therapy, 60% had a history of dialysis,
and in 20% one or more kidney transplants had been
performed. Overall, 59% of patients had received
eculizumab.
Scientific oversight, governance and coordination of
the Global aHUS Registry are provided by an independ-
ent scientific advisory board (SAB). The SAB includes
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members with expertise in key specialties related to
management of aHUS (e.g. adult and paediatric nephrol-
ogists, haematologists, and/or transplant nephrologists/
surgeons) as well as representation from Alexion
Pharmaceuticals. Also, as a result of the engagement
process described here, a patient representative is now
included on the SAB. Data collected by the Global aHUS
Registry are accessible to participating and nonpartici-
pating physicians who may request data access or spe-
cific analyses by submitting a concept sheet via the
aHUS Registry website (http://www.ahusregistry.com/)
for evaluation by the SAB.
Here, we describe the feasibility of a new model of
collaboration between an international group of patient
organisations with a rare disease and an industry-
supported disease registry, as a way to promote patient-
centred research.
Methods
The Global Registry SAB
In order to improve registry management transparency
and data analysis, the Global aHUS Registry SAB mem-
bers discussed methods to promote patient benefit from
participation and disease information sharing. Thus, in
May 2014, the SAB members resolved to invite a repre-
sentative from a patient organisation to join the SAB
with the objective of strengthening the collaboration be-
tween academic experts and patient organisations in
order to further understand patients’ needs and how the
aHUS Registry could help address them. The relation-
ships between the stakeholders involved in the Global
Registry are shown in Fig. 1.
The aHUS Alliance
In January 2013, representatives of patient organisations
from six European countries advocating on behalf of
aHUS patients met and agreed to collaborate as the
aHUS Alliance (from Belgium, France, Italy, Russia,
Spain and UK). Since then a further 6 organisations have
become affiliated to the aHUS Alliance (from Australia,
Canada, Germany, India, Netherlands and USA; http://
www.ahusallianceaction.org/patient-associations/). One
of the Alliance’s aims, listed in the inaugural “Declaration
of Collaborative Aspirations”, was to work with inter-
national clinical aHUS research networks. In order to
identify and prioritise areas of interest, the aHUS
Alliance devised a questionnaire to conduct a global
survey of patients with aHUS in 2014. The survey
was available in English, French, Spanish, German,
Italian and Dutch, and contained 28 questions seeking
details of basic patient characteristics plus feedback on six
issues commonly raised by patients with rare diseases;
diagnosis, treatment, expert centres, research, registries
and availability of information [18]. A similar survey was
conducted in 2016, updated to include 46 questions [19].
The survey was promoted via social media and available
on the Rare Connect and, in 2016, the aHUS Alliance
websites.
Furthermore, following the approach by the aHUS
Registry SAB about participating in its work, at its
second General Meeting the Alliance elected a represen-
tative to sit on the Registry SAB. The primary roles of
the patient advocate member of the SAB are described
in Table 1.
To fulfil the aim of informing the SAB of research
areas patients with aHUS considered the most import-
ant, the subject was included on the agenda for the third
meeting of the aHUS Alliance in June 2015. Members
were reminded about the call for research ideas to be
brought to the meeting.
The session was facilitated by the Alliance’s aHUS
registry representative. Initially there was a reluctance by
Fig. 1 Stakeholder collaboration in the aHUS Global Registry. Patient organisations, individual investigators, national coordinators and Alexion
Pharmaceuticals have direct representation on the Global Registry SAB. Individual investigators and national coordinators can also contact the
sponsor, a process facilitated by the clinical research organisation responsible for the Registry
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the 22 representatives to respond, with an apprehension
about articulating ideas in a way suitable for academics,
disbelief that patient opinions would be considered ser-
iously, and an unwillingness to give ideas to a commer-
cial organisation for their perceived gain. To encourage
contributions, it was highlighted that the Alliance would
not critique, or assess in terms of the Registry data avail-
able, any proposals that were made.
A preliminary report was made available to all affili-
ates of the aHUS Alliance via an online file storage fa-
cility to allow other suggestions to be added. The final
collated research suggestions were provided to the
Chair of the aHUS Registry and reported to the SAB by
the aHUS Alliance representative in November 2015
for consideration.
Results
aHUS Alliance global surveys
Overall, responses were received from 214 patients or
caregivers from 17 countries in 2014 and 233 respon-
dents from 23 countries in 2016. Of those who
responded, approximately a third reported they had par-
ticipated in research (Fig. 2). In the 2016 survey, of the
96 responders who had not been involved in research,
85 (89%) said they would like to know how to
participate.
In the 2014 and 2016 surveys, a similar proportion re-
ported being involved in any patient registry (45% and
42%, respectively), and in 2016 only 1% of respondents
did not wish to participate (Fig. 3). Around 30% of re-
sponders in both surveys did not know if they or the
person with aHUS they cared for were enrolled in a
registry. Overall, there was a trend with time towards a
more active and positive patient role in research.
When asked what would encourage greater patient
participation in research studies or clinical trials, three
options were selected by approximately half of the re-
spondents (Fig. 4). All the options, which covered receiv-
ing more information in one form or another, were
selected by at least 30% of respondents.
Classification and prioritisation of patient research
proposals
In total, 24 ideas for research were generated. The ideas
were then classified under seven categories (Table 2).
Understanding the factors that cause a TMA manifest-
ation provided the highest number of questions,
followed by those around learning more about the clin-
ical and psychological/social impact of living with the
disease on patients and families. A wish to know about
comparable aHUS patient characteristics provided the
third highest number of topics. The categorised list was
Table 1 Main roles and commitments of the patient advocacy
representative on the Global aHUS Registry SAB
Promoting interest in the Registry among patients with aHUS
• Generate programme awareness and interest within the patient
community
• Assist with involvement of patient support groups and individual patients
• Provide information on the aHUS Registry to potential patients
• Provide advice and support to patients on aHUS Registry-related matters
Providing input to the SAB on patient priorities
• Act as the interface with other patient advocacy groups to provide a
broad patient perspective from multiple countries to the Registry
• Inform the Registry of analyses and scientific questions of interest to
the patient community
• Propose, discuss and evaluate programme objectives with the Registry
SAB
• Provide ad hoc review of patient-related documents such as informed
consent forms, patient leaflets and similar materials
aHUS atypical haemolytic uraemic syndrome, SAB scientific advisory board
Fig. 2 Involvement in aHUS research as reported by aHUS Alliance survey respondents in 2014 and 2016
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then presented to aHUS Alliance members and each
country was requested to state its top five research
priorities. The votes were well distributed among the 24
ideas revealing many topics were considered of interest.
The highest scoring research topics are highlighted in
bold (Table 2).
Discussion
The effective engagement of patients in research on rare
diseases is currently an area of increasing interest [8, 20].
This has come about as a result of governments giving
greater priority and incentives for rare disease research,
including through orphan drug legislation, [21, 22] and
promotion by policy makers [20, 23]. This has occurred in
parallel with a recent shift from a passive role for patients
in research towards a desire to play a more involved role
in the research process, as demonstrated by the survey
outcomes. The lack of awareness of registry participation
amongst respondents to the aHUS Alliance survey may be
an area in which patient involvement in research can eas-
ily be improved. Patients may be unaware of the oppor-
tunity to enrol in a research registry if it is not offered by
their physician. The fact that the Registry SAB initiated
the collaboration by inviting a patient representative to
join the team demonstrates that cooperation is bidirec-
tional and reflects the recent change towards a new model
of participation in research.
Fig. 3 Enrolment in an aHUS patient registry as reported by aHUS Alliance survey respondents in 2014 and 2016
Fig. 4 Responses to aHUS Alliance 2016 survey question on how to encourage patient participation in research. Patients were asked “In your
opinion, what would encourage greater patient participation in research studies or clinical trials?”. Responses were fixed (no free text option) and
more than one option could be selected. This question was only included in the 2016 survey
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Amongst the research priorities identified, two diagno-
sis issues feature prominently. First, understanding the
barriers to more rapid diagnosis and, second, how
quickly diagnosis needs to be made to avoid irreversible
organ damage. Understandably, a key concern of pa-
tients was around outcomes following kidney transplant-
ation. This procedure was contraindicated in patients
diagnosed with aHUS prior to the availability of eculizu-
mab, and transplantation can also induce de novo aHUS.
In some countries, aHUS patients on dialysis may be re-
fused access to prophylactic eculizumab to prevent post-
transplant recurrence of the disease and therefore this is
a key issue for patient organisations around the world.
However, data on this topic have been published in the
medical literature, suggesting that the information avail-
able to patients with aHUS is poor. In this regard, pa-
tient organisations need to improve the dissemination
of relevant information to patients and the participation
of the aHUS Alliance in the Global Registry is an
opportunity for patient organisations to inform and
answer patient questions in a consistent and under-
standable way.
Table 2 Final questions and priority research areas from patients with aHUS and the aHUS Alliance
Topic Questiona Scoreb
1. Disease onset • How transient is aHUS due to pregnancy and is there a role for prophylactic eculizumab in some
cases?
10
• Does the incidence of aHUS vary in different environments e.g., urban, rural, coastal? 5
• Are hormone changes during key life-stages a significant cause of aHUS onset? 5
• Can boys with aHUS on-set at a young age grow out of it? 3
• Do annual cycles in immune activity predict a time of year when aHUS onset is more likely? 2
• Are those over 60 years-old with a genetic predisposition but no previous symptoms unlikely to develop
aHUS or are they still at risk?
0
2. Diagnosis • What are the barriers to diagnosis, and how can they be overcome? 15
• Can the degree of kidney function recovery be predicted by the time between aHUS onset and
diagnosis/treatment?
9
• Is there a “golden period” for diagnosis which can predict more favourable outcomes for patients with
aHUS?
8
3. Eculizumab treatment • Is it possible to ensure the effectiveness of eculizumab in the body? 9
• For how many days does eculizumab remain effective following administration and does it vary between
patients?
0
4. Clinical effects • What are the outcomes of a transplant without eculizumab and what non-kidney damage is likely
from any resulting aHUS onset?
20
• What is the incidence of (multi-organ) co-morbidities with aHUS for adults and children? 0
• Are there differences between adults and children in terms of co-morbidities? 0
5. Psychological/social effects • Is there any evidence as to whether not knowing the genetic cause or undergoing genetic testing causes
the most anxiety?
4
• What is the impact on the working life of adult patients with aHUS and carers of patients with aHUS? 0
• What is the impact on education for children with aHUS? 0
• What is the attitude of parents towards genetic screening of children? 0
• What are the comparative self-esteem levels of patients with aHUS undergoing different treatment
modalities?
0
• To help family planning decision, can a risk matrix of the potential harm to a mother or child be
developed?
0
6. Self-monitoring • Can a blood test be developed to allow patients in remission to monitor themselves? 9
7. Patient differences • What is the spectrum of the aHUS cohort in each country, and are there significant differences between
them?
2
• Is it possible to predict which patients will have the longest time in remission and which will be at the
highest risk on new aHUS onset?
1
• Does the spectrum of the aHUS cohort in each country change over time? 0
• What is the frequency of my specific genetic predisposition in my country and other countries? 0
aQuestions have been reproduced as formulated by the patient groups with only minor editing for clarity
bCountries comprising the aHUS Alliance were invited to vote for up to five research questions, which were scored as 5 points; most interesting, to 1 point; fifth
most interesting. The sum of the scores received are reported. The top scoring questions are shown in bold
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An ability to self-monitor aHUS symptoms also fea-
tured strongly, reflecting a desire of patients to feel in
control of their condition. The issue of the time of year
of aHUS onset has its roots in a casual discussion in the
aHUS social media, but may be worthy of further study.
Although not selected as a priority area of research,
several members of the aHUS Alliance have an interest
in this subject and a proposal to investigate this has been
submitted to the SAB for consideration. Further, some
of the questions raised demonstrate a potential lack of
understanding of the disease and represent an opportun-
ity for development of educational materials to address
patient knowledge gaps.
Interestingly, no questions were raised regarding po-
tential adverse effects of eculizumab, such as the risk of
meningococcal infection, despite the primary purpose of
the Registry being to determine the long-term safety of
eculizumab treatment. This could be due a number of
reasons, including physicians and patients considering
the risk negligible, or the provision of patient informa-
tion cards on treatment initiation and advice from pa-
tient organisations is sufficient explanation.
Following presentation of the report by the aHUS
Alliance’s SAB representative, the research topics were
given serious consideration for action. It was considered
that a response to the aHUS Alliance’s list, including
identification of knowledge gaps, would be a prerequisite
to complete prioritisation. The subsequent work plan for
the aHUS Registry in 2016 featured a number of topics
proposed by the Alliance as priority activities. The aHUS
Alliance had therefore not only been consulted but their
response was considered and incorporated, creating a
clear process of engagement for working with an
international research network. This innovative way of
generating research ideas has also been a learning
process for the SAB members. For both parties to get
the most from the collaboration, it is important to en-
sure the development of a long-term partnership.
A paradigm shift for patient participation in disease-related
research decision-making?
Patients with rare diseases have limited access to useful
information to guide treatment decisions; providing pa-
tients with the opportunity to ask research questions
may help to ensure that research efforts in rare diseases
address relevant clinical questions and patient-centred
health outcomes [20]. The active participation of pa-
tients and their representatives in research, whether a
registry or clinical trial, can potentially lead to improve-
ments in enrolment, data collection and quality, the
credibility of results and their direct applicability to pa-
tients [24]. The inclusion of a patient representative on
the Global aHUS Registry SAB will also improve the
dissemination of outcomes to patients, thus increasing
the transparency of the research process.
In order to promote changing the role of the patient
in a registry from passive (patient is a data point) to ac-
tive (patient is a researcher), [24] the participation of pa-
tients in the Global aHUS Registry is now actively
supported by a patient representative working alongside
the SAB. The patient advocate will assist in developing
strategies to encourage voluntary patient participation in
the Registry, will convey information from patients
about their experience with the Registry, and will help
the SAB share the results of the Registry with other
patients.
A formal structure for partnerships between patient
groups and clinical researchers
The Dialogue Model [25] has been identified as a con-
struct for the continuing development of the partnership
in the context of the Registry. The Model has six stages
(exploration, consultation, prioritisation, integration,
programming and implementation), of which the emer-
ging partnership has reached the start of the third stage.
Not completing the early stages fully and satisfactorily
can be predictive of a failure to sustain progress to suc-
cessful implementation.
Completion of a robust systematic evidence assess-
ment review of the knowledge gap needs to be reviewed
by the SAB as well as the Alliance, to arrive at an agreed
list of specific patient research priorities, which then
must be integrated with the Registry’s other research
agendas from clinicians and industry. With an integrated
list of research topics finalised, it will then be possible to
move to a sequential programming of topics for direct
study by the SAB, or indirectly, through encouragement
of external investigators to use the Registry data for
other priority topics.
Conclusions
The ongoing participation of patient advocacy groups in
the activities of the Global aHUS Registry will help the
Registry achieve its aims of establishing a robust data-
base of patients with aHUS, characterising the long-term
natural history of the disease, and enhancing the under-
standing of aHUS by publishing analyses of registry data.
Engagement of patients with rare diseases in clinical re-
search may promote research efforts directed to relevant
clinical questions and patient-centred health outcomes.
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